Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Results of second-line therapy in adult Philadelphia chromosome-posit… Blinatumomab · PMID 42482409 | Lupus · Myasthénie · Myasthénie | À vérifier | Publication | PubMed | Voir la publication source The approval of the BCR::ABL tyrosine kinase inhibitors (TKIs) and blinatumomab have improved outcomes in Ph-positive B… | Cancer 2026-07-22 21:23:17 | Source |
| Exploring low clozapine C/D ratios, inverted clozapine-norclozapine r… Medication Adherence and Non-adherence in Adults With Rare Disease · PMID 37487869 | Myasthénie | Thérapie génique | Publication | PubMed | Voir la publication source Up to 1/2 of outpatients prescribed clozapine may be partially/fully non-adherent, based on therapeutic drug monitoring… | Schizophrenia research 2026-07-22 21:23:15 | Source |
| Non-Adherence to Standard Therapy in Autoimmune Hepatitis: Impact of… Medication Adherence and Non-adherence in Adults With Rare Disease · PMID 40748765 | Myasthénie | À vérifier | Publication | PubMed | Voir la publication source Non-adherence to treatment may be one of the most important causes for the failure of therapy goals in autoimmune liver… | United European gastroenterology journal 2026-07-22 21:23:15 | Source |
| Randomized phase I trial outcomes show safe and sustainable inhibitio… Empasiprubart IV · PMID 40819168 | Myasthénie | À vérifier | Publication | PubMed | Voir la publication source Activation of classical and lectin complement pathways contributes to several human diseases. Empasiprubart is a humani… | Nature communications 2026-07-22 21:23:15 | Source |
| Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein,… RC18 240 mg · PMID 35107091 | Lupus | Immunomodulation | Publication | PubMed | Voir la publication source Systemic lupus erythematosus (SLE) is a chronic autoimmune disease, in which aberrant immune cells and proinflammatory… | Drugs of today (Barcelona, Spain : 1998) 2026-07-22 21:23:13 | Source |
| Pneumocystis jirovecii pneumonia and prophylaxis in patients with sol… Prednisone · PMID 42484810 | Cancer · Lupus · Myasthénie · Myopathies · Sclérose en plaques · Myas… | À vérifier | Publication | PubMed | Voir la publication source Pneumocystis jirovecii pneumonia (PJP) is an uncommon but potentially fatal opportunistic fungal infection in immunocom… | Clinical & translational oncology : official publicati… 2026-07-22 21:23:10 | Source |
| Sympathetic ophthalmia induced by vitrectomy for endogenous fungal en… Prednisone · PMID 42482889 | Cancer · Lupus · Myasthénie · Myopathies · Sclérose en plaques · Myas… | Immunomodulation | Publication | PubMed | Voir la publication source Sympathetic ophthalmia (SO) is a rare but serious inflammatory ocular disorder. We report a case of endogenous fungal e… | Frontiers in medicine 2026-07-22 21:23:10 | Source |
| Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Ar… Control Group · PMID 42485024 | Myasthénie · Sclérose en plaques | Traitement symptomatique | Publication | PubMed | Voir la publication source Evidence regarding efficacy and safety of thrombectomy in acute ischemic stroke (AIS) due to medium or distal vessel oc… | JAMA 2026-07-22 21:23:03 | Source |
| The effect of an interactive game played with women of reproductive a… Control Group · PMID 42485092 | Myasthénie · Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Globally, access to menstrual cycle and hygiene information is limited, especially for women who are largely hearing im… | Disability and rehabilitation. Assistive technology 2026-07-22 21:23:03 | Source |
| Clinical similarity in cost-comparison evaluations: a systematic revi… Ravulizumab · PMID 42481194 | Myasthénie | Thérapie génique | Publication | PubMed | Voir la publication source To review how statistically non-significant indirect treatment comparison (ITC) results are interpreted within National… | BMJ open 2026-07-22 21:23:02 | Source |
| Sustained terminal complement inhibition on the endothelium with ravu… Ravulizumab · PMID 42479640 | Myasthénie | Thérapie génique | Publication | PubMed | Voir la publication source Atypical haemolytic uremic syndrome (aHUS) is a rare and severe form of thrombotic microangiopathy caused by dysregulat… | Nephron 2026-07-22 21:23:02 | Source |
| Selective pulmonary vasorelaxant effects of an N,N-diaminoquinazoline… Sildenafil · PMID 42468673 | Hypertension artérielle | À vérifier | Publication | PubMed | Voir la publication source Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary vascular resistance… | European journal of pharmacology 2026-07-22 21:23:01 | Source |
| Sildenafil-associated severe cholestatic drug-induced liver injury pr… Sildenafil · PMID 42474650 | Migraine · Myopathies · Myopathies · Migraine | Traitement symptomatique | Publication | PubMed | Voir la publication source Sildenafil is widely used as a phosphodiesterase type 5 inhibitor for erectile dysfunction. Drug-induced liver injury (… | Clinical journal of gastroenterology 2026-07-22 21:23:01 | Source |
| Beyond awareness: evaluating the impact of a hospital-wide, multi-sta… GenPHSat injection (Safety) · PMID 42483475 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source Infection prevention is fundamental to patient safety, yet conventional audits often fall short in driving sustained be… | GMS hygiene and infection control 2026-07-22 21:22:56 | Source |
| Combined anti-VEGF and intravitreal dexamethasone treatment versus an… GenPHSat injection (Safety) · PMID 42484199 | Myopathies | Thérapie génique | Publication | PubMed | Voir la publication source This systematic review and meta-analysis aimed to compare the effectiveness and safety profiles of anti-vascular endoth… | Arquivos brasileiros de oftalmologia 2026-07-22 21:22:56 | Source |
| Glycosylation penetrance of N-X-S/T sequons in antibody variable doma… Glutamine · PMID 42482306 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Machine learning (ML) approaches for de novo antibody design generate thousands of candidate sequences, but most lack a… | mAbs 2026-07-22 21:22:55 | Source |
| Palometa fish (Serrasalmus maculatus) meat: Amino acids profile by ga… Glutamine · PMID 42484164 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Palometa (Serrasalmus maculatus) is a predatory freshwater fish that is abundant in South America. Palometa is rarely c… | Anais da Academia Brasileira de Ciencias 2026-07-22 21:22:55 | Source |
| From Visceral Pain to Emotional Distress: Comparative Effectiveness o… Desipramine · PMID 42470701 | Myopathies | Traitement symptomatique | Publication | PubMed | Voir la publication source Antispasmodics and antidepressants are standard therapies for managing both the gastrointestinal symptoms and psycholog… | Journal of gastrointestinal and liver diseases : JGLD 2026-07-22 21:22:52 | Source |
| Guillain-Barré syndrome with bilateral extensor plantar responses: A… IvIg · PMID 42483360 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy, typically presenting with rapidly pro… | Journal of family medicine and primary care 2026-07-22 21:22:50 | Source |
| Hormonal Contraception and Initiation of Semaglutide Therapy. Behavioral Interventions for Controlling Oral Behaviors · PMID 42485041 | Myopathies | À vérifier | Publication | PubMed | Voir la publication source Concerns regarding weight changes during hormonal contraceptive use may influence health care-seeking behavior and cont… | JAMA network open 2026-07-22 21:22:49 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||